Abstract
Systemic therapy has been viewed as the mainstay for de novo metastatic breast cancer (dnMBC). However, as dnMBC is highly heterogeneous both biologic......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
